Czech medtech startup Kardi Ai has raised €5.3 million in a Series A funding round led by German HealthTech VC fund Callisto Health, with participation from Česká spořitelna and Slovenská sporiteľňa through Seed Starter, alongside BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels.
Kardi Ai develops a technology platform for long-term heart rhythm monitoring and the early detection of potential heart rhythm disorders. Its solution combines a fitness chest strap equipped with an electrocardiogram (ECG) sensor, a mobile application and AI-powered analysis of ECG recordings.
Traditional cardiac examinations typically capture heart activity over a limited period, potentially missing irregularities that occur intermittently. Kardi Ai aims to address this limitation by enabling patients to monitor their heart rhythm during everyday activities, generating data that can help physicians identify potential problems and determine whether further medical attention is needed. The system does not provide diagnoses but supports clinical decision-making through long-term monitoring and analysis.
In the Czech Republic, Kardi Ai works with more than 70 hospitals and over 20 corporate and employee-benefit partners, with its technology used by more than 6,000 people. According to the company, its monitoring system has identified possible cardiac arrhythmias in approximately one quarter of users, including more than 500 findings classified as critical.
The company has also expanded into Slovakia, where it works with more than 20 physicians, primarily cardiologists, following its market entry several months ago.
Beyond its domestic market, Kardi Ai has established operations in Poland, Romania and Bulgaria, while preparing to enter Germany following the completion of pilot projects. The company has also secured regulatory approvals supporting its planned expansion into India and the United Arab Emirates, and is completing the medical device approval process in Singapore.
We are gradually moving beyond detecting heart rhythm disorders towards technology capable of identifying an increased risk before arrhythmia manifests. Nearly two billion people live in the markets where we already operate or are preparing to launch.
The new capital will allow us to validate this technology at global scale and across patient demographics and pursue our ambition to become a leading provider of long-term ECG monitoring in these markets,
said Vlastimil Hrabal, co-founder and CEO of Kardi Ai.
The new funding will support Kardi Ai's expansion across Europe and Asia, with Germany among its immediate priorities, alongside planned market entries in India, the United Arab Emirates and Singapore.
The company also intends to develop predictive models that analyse data from multiple ECG measurements to estimate the risk of cardiac arrhythmias before they occur. These models remain under development and will require clinical validation and regulatory approval before being introduced into medical practice.
Would you like to write the first comment?
Login to post comments